Expression and function of the novel proto-oncogene PBF in thyroid cancer: A new target for augmenting radioiodine uptake

Journal of Endocrinology

Volumn 210, Issue 2, 2011, Pages 157-163

  Smith, Vicki E ^a   Franklyn, Jayne A ^a   McCabe, Christopher J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; CD63 ANTIGEN; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; ONCOPROTEIN; PITUITARY TUMOR TRANSFORMING GENE BINDING FACTOR PROTEIN; RADIOACTIVE IODINE; UNCLASSIFIED DRUG; VASCULOTROPIN; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; TUMOR PROTEIN;

CARCINOGENESIS; DISEASE ASSOCIATION; DRUG UPTAKE; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; THYROID CANCER; UMBILICAL VEIN ENDOTHELIAL CELL; GENETICS; METABOLISM; THYROID GLAND; THYROID TUMOR;

HUMANS; NEOPLASM PROTEINS; PROGNOSIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 80052590691     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0064     Document Type: Review

References (32)

1. Bernard Cher TH, Chan HS, Klein GF, Jabkowski J, Schadenbock-Kranzl G, Zach O, Roca X & Alex Law SK 2011 A novel 30 splice-site mutation and a novel gross deletion in leukocyte adhesion deficiency (LAD)-1. Biochemical and Biophysical Research Communications 404 1099-1104.
2. Boelaert K,McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL,Watkinson JC, Bradwell AR, Sheppard MC & Franklyn JA 2003 Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 88 2341-2347.
3. Boelaert K, Yu R, Tannahill LA, Stratford AL, Khanim FL, Eggo MC, Moore JS, Young LS, Gittoes NJ, Franklyn JA et al. 2004 PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. Journal of Molecular Endocrinology 33 663-677.
4. Boelaert K, Smith VE, Stratford AL, Kogai T, Tannahill LA, Watkinson JC, Eggo MC, Franklyn JA & McCabe CJ 2007 PTTG and PBF repress the human sodium iodide symporter. Oncogene 26 4344-4356.
5. Bork P, Doerks T, Springer TA & Snel B 1999 Domains in plexins: links to integrins and transcription factors. Trends in Biochemical Science 24 261-263.
6. ChienW& Pei L 2000 A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. Journal of Biological Chemistry 275 19422-19427.
7. Heaney AP, Nelson V, Fernando M & Horwitz G 2001 Transforming events in thyroid tumorigenesis and their association with follicular lesions. Journal of Clinical Endocrinology and Metabolism 86 5025-5032.
8. Ishikawa H, Heaney AP, Yu R, Horwitz GA & Melmed S 2001 Human pituitary tumor-transforming gene induces angiogenesis. Journal of Clinical Endocrinology and Metabolism 86 867-874.
9. - symport activity is present in membrane vesicles from thyrotropin-deprived non-I(-)-transporting cultured thyroid cells. PNAS 91 3789-3793.
10. Kim DS, Franklyn JA, Stratford AL, Boelaert K, Watkinson JC, Eggo MC & McCabe CJ 2006 Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 1119-1128.
11. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A & Onaya T 1997 Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138 2227-2232.
12. Kogai T, Taki K & Brent GA 2006 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocrine-Related Cancer 13 797-826.
13. Lin X, Ryu KY & Jhiang SM 2004 Cloning of the 50-flanking region of mouse sodium/iodide symporter and identification of a thyroid-specific and TSH-responsive enhancer. Thyroid 14 19-27.
14. Lyle R, Bena F, Gagos S, Gehrig C, Lopez G, Schinzel A, Lespinasse J, Bottani A, Dahoun S, Taine L et al. 2009 Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. European Journal of Human Genetics 17 454-466.
15. Mazzaferri EL & Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 86 1447-1463.
16. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA et al. 2003 Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology 58 141-150.
17. Mo Z, Zu X, Xie Z, LiW,Ning H, Jiang Y & Xu W 2009 Antitumor effect of F-PBF(beta-TrCP)-induced targeted PTTG1 degradation in HeLa cells. Journal of Biotechnology 139 6-11.
18. Pei L 2001 Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. Journal of Biological Chemistry 276 8484-8491.
19. Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E et al. 2010 Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 465 813-817.
20. Riedel C, Levy O & Carrasco 2001 Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. Journal of Biological Chemistry 276 21458-21463.
21. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M & Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of NaC/IK targeting to the membrane. Endocrine-Related Cancer 13 257-269.
22. Riesco-Eizaguirre G, Rodriguez I, De l V, Costamagna E, Carrasco N, Nistal M& Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer 69 8317-8325.
23. Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, Tortolero M, Pintor-Toro JA & Japon MA 2006 Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 1404-1409.
24. Smith VE, Read ML, Turnell AS,Watkins RJ,Watkinson JC, Lewy GD, Fong JC, James SR, Eggo MC, Boelaert K et al. 2009 A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. Journal of Cell Science 122 3393-3402.
25. Smith VE, Franklyn JA & McCabe CJ 2010 Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Reviews in Molecular Medicine 12 e38.
26. Stratford AL, Boelaert K, Tannahill LA, Kim DS, Warfield A, Eggo MC, Gittoes NJ, Young LS, Franklyn JA & McCabe CJ 2005 Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism 90 4341-4349.
27. Taki K, Kogai T, Kanamoto Y, Hershman JM & Brent GA 2002 A thyroidspecific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Molecular Endocrinology 16 2266-2282.
28. Vadysirisack DD, Chen ES, Zhang Z, Tsai MD, Chang GD & Jhiang SM 2007 Identification of in vivo phosphorylation sites and their functional significance in the sodium iodide symporter. Journal of Biological Chemistry 282 36820-36828.
29. Vlotides G, Eigler T & Melmed S 2007 Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews 28 165-186.
30. Watkins RJ, Read ML, Smith VE, Sharma N, Reynolds GM, Buckley L, Doig C, Campbell MJ, Lewy G, Eggo MC et al. 2010 Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Research 70 3739-3749.
31. Yaspo ML, Aaltonen J, Horelli-Kuitunen N, Peltonen L & Lehrach H 1998 Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics 49 133-136.
32. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD & Melmed S 1999 Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 13 156-166.